Jpmorgan Chase & CO Taysha Gene Therapies, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3,001,397 shares of TSHA stock, worth $6.36 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,001,397
Previous 2,963,553
1.28%
Holding current value
$6.36 Million
Previous $6.64 Million
9.13%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding TSHA
# of Institutions
119Shares Held
136MCall Options Held
25.9KPut Options Held
24K-
Avoro Capital Advisors LLC New York, NY18.7MShares$39.5 Million0.56% of portfolio
-
Rtw Investments, LP New York, NY14.9MShares$31.7 Million0.48% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$24.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$23 Million0.3% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$19.1 Million1.87% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $103M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...